Cargando…

Function and clinical meaningfulness of treatments for mild Alzheimer's disease

INTRODUCTION: Effectiveness of Alzheimer's disease (AD) treatments is commonly evaluated with coprimary outcomes; cognition with function to ensure clinical meaningfulness of a cognitive effect. METHODS: We reviewed the literature for functional outcomes in mild AD or mild cognitive impairment...

Descripción completa

Detalles Bibliográficos
Autores principales:	Siemers, Eric, Holdridge, Karen Chilcott, Sundell, Karen L., Liu-Seifert, Hong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2016
Materias:	Diagnostic Assessment & Prognosis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879645/ https://www.ncbi.nlm.nih.gov/pubmed/27239541 http://dx.doi.org/10.1016/j.dadm.2016.02.006

Ejemplares similares

Assessing quality of life in Alzheimer's disease: Implications for clinical trials
por: Kahle-Wrobleski, Kristin, et al.
Publicado: (2016)

Early diagnosis of mild cognitive impairment and Alzheimer's disease based on salivary lactoferrin
por: Carro, Eva, et al.
Publicado: (2017)

Metabolic correlates of prevalent mild cognitive impairment and Alzheimer's disease in adults with Down syndrome
por: Mapstone, Mark, et al.
Publicado: (2020)

What outcomes are important to patients with mild cognitive impairment or Alzheimer's disease, their caregivers, and health-care professionals? A systematic review
por: Tochel, Claire, et al.
Publicado: (2019)

Revolutionizing Alzheimer's disease and clinical trials through biomarkers
por: Mattsson, Niklas, et al.
Publicado: (2015)

Clinical and biomarker trajectories in sporadic Alzheimer's disease: A longitudinal study
por: Wang, Hui‐Fu, et al.
Publicado: (2020)

Characterizing heterogeneity in the progression of Alzheimer's disease using longitudinal clinical and neuroimaging biomarkers
por: Goyal, Devendra, et al.
Publicado: (2018)

Diagnosed prevalence of Alzheimer's disease and related dementias in Medicare Advantage plans
por: Jutkowitz, Eric, et al.
Publicado: (2020)

Longitudinal evaluation of criteria for subjective cognitive decline and preclinical Alzheimer's disease in a memory clinic sample
por: Eckerström, Marie, et al.
Publicado: (2017)

Alzheimer's disease severity, objectively determined and measured
por: Gross, Alden L., et al.
Publicado: (2016)

Periodontal disease's contribution to Alzheimer's disease progression in Down syndrome
por: Kamer, Angela R., et al.
Publicado: (2016)

Cerebrospinal fluid biomarkers of Alzheimer's disease in a cohort of adults with Down syndrome
por: Henson, Rachel L., et al.
Publicado: (2020)

Detection of presymptomatic Alzheimer's disease through breath biomarkers
por: Emam, Shadi, et al.
Publicado: (2020)

Is diabetes associated with increased pathological burden in Alzheimer's disease?
por: Sadrolashrafi, Kaviyon, et al.
Publicado: (2021)

Challenges associated with biomarker-based classification systems for Alzheimer's disease
por: Illán-Gala, Ignacio, et al.
Publicado: (2018)

Development and validation of a salivary tau biomarker in Alzheimer's disease
por: Pekeles, Heather, et al.
Publicado: (2018)

Multimodal prediction of conversion to Alzheimer's disease based on incomplete biomarkers
por: Ritter, Kerstin, et al.
Publicado: (2015)

The Consortium for the early identification of Alzheimer's disease–Quebec (CIMA-Q)
por: Belleville, Sylvie, et al.
Publicado: (2019)

Prognostic value of ATN Alzheimer biomarkers: 60‐month follow‐up results from the Argentine Alzheimer's Disease Neuroimaging Initiative
por: Allegri, Ricardo F., et al.
Publicado: (2020)

Disclosure of preclinical Alzheimer's disease biomarker results in research and clinical settings: Why, how, and what we still need to know
por: Erickson, Claire M., et al.
Publicado: (2021)

Projection of budgetary savings to US state Medicaid programs from reduced nursing home use due to an Alzheimer's disease treatment
por: Lam, Jenny, et al.
Publicado: (2021)

Underdiagnosis of mild cognitive impairment: A consequence of ignoring practice effects
por: Elman, Jeremy A., et al.
Publicado: (2018)

Random forest to differentiate dementia with Lewy bodies from Alzheimer's disease
por: Dauwan, Meenakshi, et al.
Publicado: (2016)

Relationship between frailty and Alzheimer's disease biomarkers: A scoping review
por: Wallace, Lindsay, et al.
Publicado: (2018)

Copper and zinc isotopic excursions in the human brain affected by Alzheimer's disease
por: Moynier, Frédéric, et al.
Publicado: (2020)

Theoretical frameworks and approaches used within the Reserve, Resilience and Protective Factors professional interest area of the Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment
por: Bartrés‐Faz, David, et al.
Publicado: (2020)

Neuropsychiatric symptoms in Brazilians with mild cognitive impairment and dementia
por: Wilson, Robert S., et al.
Publicado: (2021)

Developmental lead exposure and lifespan alterations in epigenetic regulators and their correspondence to biomarkers of Alzheimer's disease
por: Eid, Aseel, et al.
Publicado: (2016)

Pilot study of an Alzheimer's disease risk assessment program in a primary care setting
por: Korthauer, Laura E., et al.
Publicado: (2021)

Standardizing salivary lactoferrin measurements to obtain a robust diagnostic biomarker for Alzheimer's disease
por: Bartolome, Fernando, et al.
Publicado: (2021)

Patterns of glucose hypometabolism in Down syndrome resemble sporadic Alzheimer's disease except for the putamen
por: Zammit, Matthew D., et al.
Publicado: (2021)

Progression and predictors of mild cognitive impairment in Chinese elderly: A prospective follow-up in the Shanghai Aging Study
por: Ding, Ding, et al.
Publicado: (2016)

Low eGFR is associated with dysexecutive and amnestic mild cognitive impairment
por: Zammit, Andrea R., et al.
Publicado: (2015)

The incidence of mild cognitive impairment: A systematic review and data synthesis
por: Gillis, Cai, et al.
Publicado: (2019)

Practical algorithms for amyloid β probability in subjective or mild cognitive impairment
por: Maserejian, Nancy, et al.
Publicado: (2019)

Blood metabolites predicting mild cognitive impairment in the study of Latinos‐investigation of neurocognitive aging (HCHS/SOL)
por: He, Shan, et al.
Publicado: (2022)

Moderate intensity physical activity associates with CSF biomarkers in a cohort at risk for Alzheimer's disease
por: Law, Lena L., et al.
Publicado: (2018)

Tauopathy in basal ganglia involvement is exacerbated in a subset of patients with Alzheimer's disease: The Hisayama study
por: Hamasaki, Hideomi, et al.
Publicado: (2019)

Bayesian latent time joint mixed-effects model of progression in the Alzheimer's Disease Neuroimaging Initiative
por: Li, Dan, et al.
Publicado: (2018)

Mild cognitive impairment and dementia prevalence: The Atherosclerosis Risk in Communities Neurocognitive Study
por: Knopman, David S., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_4g8blkdlb4vk0eock4mh850chc